Differential Expression of Phospho-S6 in Hair Follicle Tumors: Evidence of Mammalian Target of Rapamycin Pathway Activation

January 2019 in “ Journal of cutaneous pathology ”

Luis A. Sardiña, Brian P. Rubin, George Jour, Melissa Piliang, Carly Elston, Wilma F. Bergfeld

phospho-S6 mTOR pathway fibrofolliculomas trichoepitheliomas tricholemmomas pilomatricomas malignant proliferating tricholemmal tumors tricholemmal carcinomas trichoblastic carcinomas mammalian target of rapamycin pathway

TLDR The mTOR pathway may be involved in the development of hair follicle tumors, with higher activity in malignant tumors.

The study investigated the expression of phospho-S6, a marker of mTOR pathway activation, in various benign and malignant hair follicle tumors. A total of 76 cases were analyzed, including fibrofolliculomas, trichoepitheliomas, tricholemmomas, pilomatricomas, malignant proliferating tricholemmal tumors, tricholemmal carcinomas, and trichoblastic carcinomas. Results showed that all malignant tumors exhibited strong and diffuse phospho-S6 staining in 70% to 90% of tumor cells. In contrast, benign tumors showed less frequent and more patchy phospho-S6 staining. The findings suggested that phospho-S6 is differentially expressed in benign versus malignant hair follicle tumors, indicating mTOR pathway activation is more prominent in malignant cases.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

research mTOR Signaling Promotes Stem Cell Activation via Counterbalancing BMP-Mediated Suppression During Hair Regeneration

71 citations, January 2015 in “Journal of molecular cell biology/Journal of Molecular Cell Biology”

mTOR signaling helps activate hair stem cells by balancing out the suppression caused by BMP during hair growth.

Similar Research

5 / 683 results

research Disruption of Tubular Flcn Expression as a Mouse Model for Renal Tumor Induction

29 citations, June 2015 in “Kidney International”

Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.

research Birt-Hogg-Dubé Syndrome: From Gene Discovery to Molecularly Targeted Therapies

39 citations, October 2012 in “Familial cancer”

New therapies for Birt–Hogg–Dubé syndrome are being developed based on understanding the FLCN gene's role.

research Pulmonary Manifestations of Birt-Hogg-Dubé Syndrome

99 citations, May 2013 in “Familial cancer”

People with Birt-Hogg-Dubé syndrome often have lung problems and delayed diagnosis, and better recognition of CT scan signs could improve diagnosis and management.

Folliculin, the Product of the Birt-Hogg-Dube Tumor Suppressor Gene, Interacts with the Adherens Junction Protein p0071 to Regulate Cell-Cell Adhesion

research Folliculin, the Product of the Birt-Hogg-Dube Tumor Suppressor Gene, Interacts with the Adherens Junction Protein p0071 to Regulate Cell-Cell Adhesion

72 citations, November 2012 in “PloS one”

The protein folliculin, involved in a rare disease, works with another protein to control how cells stick together and their organization, and changes in this interaction can lead to disease symptoms.

research Birt-Hogg-Dubé Syndrome: Genetic and Clinical Insights

7 citations, September 2013 in “Familial cancer”

Birt–Hogg–Dubé syndrome is a rare genetic condition causing skin lesions, lung cysts, and a higher chance of kidney cancer.